ArticleJournal of molecular endocrinology2026
TSH promotes chemerin/CMKLR1-cAMP/ERK-DIO2 signaling in primary rat ependymal cells in vitro.
Article in Journal of molecular endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: In mammals, chemerin and its receptor CMKLR1 might be downstream effectors in response to a long photoperiod in the ependymal cells lining the third ventricle in rats. Iodothyronine deiodinase 2 (DIO2) is a main product of the involvement of TSH in photoperiodic signaling. Thus, the potential interplay of TSH and chemerin/CMKLR1 signaling might exist during photoperiodic changes. Our study aimed to investigate whether chemerin/CMKLR1 signaling could stimulate DIO2 production and how TSH could affect chemerin/CMKLR1 signaling in primary rat ependymal cells. Colocalization of chemerin with its receptor, CMKLR1, was observed using immunohistochemistry assay. The expression of chemerin and CMKLR1 was identified using real-time PCR and western blot analysis, respectively. DIO2 expression, which involves a dual signaling pathway (an increase in cAMP levels and phosphorylation of ERK1/2), was detected by western blot assay and enzyme-linked immunosorbent assay (ELISA). Our study showed the potential interaction between chemerin and CMKLR1 in primary rat ependymal cells. TSH could upregulate the expression of chemerin and CMKLR1 in chemerin-pretreated primary ependymal cells. In vitro treatment of primary ependymal cells with chemerin (10 ng/mL) or TSH (60 mIU/mL) could induce an increase in cAMP levels, ERK1/2 phosphorylation and DIO2 expression. Furthermore, we found that TSH could promote the effect of chemerin/CMKLR1 signaling on DIO2 production through an increase in cAMP levels and the phosphorylation of ERK1/2. We concluded that chemerin/CMKLR1 signaling could enhance DIO2 activity in primary rat ependymal cells in vitro, and this effect could be promoted by TSH through cAMP and phosphorylation of ERK1/2. Main points: Chemerin/CMKLR1 interaction in primary rat ependymal cells is discussed. Chemerin/CMKLR1 signals through cAMP and ERK phosphorylation to induce deiodinase 2 expression in primary ependymal cells. TSH promotes the effect of chemerin/CMKLR1 signaling on deiodinase 2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.